Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Neumora Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 104 | 135 | +31 |
| Shares | 68.7M | 80.3M | +11.7M (+17.0%) |
| Value | $907.0M | $851.6M | −$55.4M (−6.1%) |
New holders (45)
Institutions that held Neumora Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (14)
Institutions that held Neumora Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Avidity Partners Management LP | 1,800,000 | $23.8M |
| Saturn V Capital Management LLC | 432,996 | $5.72M |
| Auour Investments LLC | 250,000 | $2.93M |
| Logos Global Management LP | 100,000 | $1.32M |
| Point72 Asset Management, L.P. | 83,077 | $1.10M |
| Dark Forest Capital Management LP | 55,489 | $733.0K |
| Corton Capital Inc. | 51,561 | $681.1K |
| Group One Trading, L.P. | 15,776 | $208.4K |
| Ballentine Partners, LLC | 13,441 | $177.6K |
| HSBC Holdings PLC | 10,067 | $133.5K |
| Acadian Asset Management LLC | 4,439 | $58.0K |
| Bessemer Group Inc | 120 | $2.00K |
| Ronald Blue Trust, Inc. | 38 | $374 |
| Capital Performance Advisors LLP | 11 | $145 |